United Therapeutics Corporation (UTHR) Insider Trading
- $999,400.80
- $964,180,770.30
- Feb. 25, 2026
- Martine A Rothblatt
| Trader Name | Date | Title | Amount | Price | Type | Total Value |
|---|---|---|---|---|---|---|
| April 4, 2014 | COO | 10,000 | $93.22 | Sell | $932,200.00 | |
| April 3, 2014 | Director | 1,500 | $95.67 | Sell | $143,505.00 | |
| April 3, 2014 | EVP | 6,000 | $93.10 | Sell | $558,600.00 | |
| April 3, 2014 | CFO | 10,000 | $93.22 | Sell | $932,200.00 | |
| April 3, 2014 | CEO | 9,066 | $93.74 | Sell | $849,846.84 | |
| April 1, 2014 | COO | 10,000 | $95.44 | Sell | $954,400.00 | |
| March 27, 2014 | CEO | 9,066 | $93.35 | Sell | $846,311.10 | |
| March 25, 2014 | COO | 10,000 | $95.64 | Sell | $956,400.00 | |
| March 21, 2014 | COO | 10,000 | $93.84 | Sell | $938,400.00 | |
| March 20, 2014 | Director | 1,500 | $96.04 | Sell | $144,060.00 | |
| March 20, 2014 | CFO | 10,000 | $96.11 | Sell | $961,100.00 | |
| March 20, 2014 | CEO | 9,065 | $96.76 | Sell | $877,129.40 | |
| March 20, 2014 | EVP | 6,000 | $96.81 | Sell | $580,860.00 | |
| March 18, 2014 | COO | 10,000 | $96.51 | Sell | $965,100.00 | |
| March 13, 2014 | CEO | 3,833 | $95.64 | Sell | $366,588.12 | |
| March 7, 2014 | COO | 10,000 | $99.02 | Sell | $990,200.00 | |
| March 6, 2014 | Director | 5,000 | $101.39 | Sell | $506,950.00 | |
| March 6, 2014 | CFO | 10,000 | $99.07 | Sell | $990,700.00 | |
| March 6, 2014 | CEO | 3,833 | $102.77 | Sell | $393,917.41 | |
| March 6, 2014 | EVP | 6,000 | $101.93 | Sell | $611,580.00 | |
| Feb. 28, 2014 | Director | 15,000 | $101.42 | Sell | $1,521,300.00 | |
| Feb. 27, 2014 | CEO | 3,833 | $100.68 | Sell | $385,906.44 | |
| Feb. 21, 2014 | COO | 10,000 | $104.89 | Sell | $1,048,900.00 | |
| Feb. 20, 2014 | CEO | 3,833 | $103.91 | Sell | $398,287.03 | |
| Feb. 20, 2014 | EVP | 6,000 | $104.63 | Sell | $627,780.00 | |
| Feb. 13, 2014 | CEO | 3,833 | $99.87 | Sell | $382,801.71 | |
| Feb. 7, 2014 | COO | 10,000 | $96.61 | Sell | $966,100.00 | |
| Feb. 6, 2014 | EVP | 6,000 | $97.41 | Sell | $584,460.00 | |
| Feb. 6, 2014 | Director | 3,000 | $97.33 | Sell | $291,990.00 | |
| Feb. 6, 2014 | CEO | 3,833 | $97.26 | Sell | $372,797.58 | |
| Jan. 30, 2014 | CEO | 3,833 | $106.25 | Sell | $407,256.25 | |
| Jan. 23, 2014 | CEO | 3,833 | $111.78 | Sell | $428,452.74 | |
| Jan. 17, 2014 | COO | 10,000 | $113.03 | Sell | $1,130,300.00 | |
| Jan. 16, 2014 | CEO | 3,833 | $111.21 | Sell | $426,267.93 | |
| Jan. 16, 2014 | EVP | 6,000 | $111.98 | Sell | $671,880.00 | |
| Jan. 9, 2014 | CEO | 3,833 | $108.35 | Sell | $415,305.55 | |
| Jan. 9, 2014 | Director | 5,000 | $110.00 | Sell | $550,000.00 | |
| Jan. 3, 2014 | COO | 10,000 | $110.72 | Sell | $1,107,200.00 | |
| Jan. 2, 2014 | Director | 3,000 | $111.41 | Sell | $334,230.00 | |
| Jan. 2, 2014 | CEO | 3,833 | $111.54 | Sell | $427,532.82 | |
| Jan. 2, 2014 | EVP | 6,000 | $110.78 | Sell | $664,680.00 | |
| Dec. 31, 2013 | CEO | 18,140 | $112.64 | Sell | $2,043,289.60 | |
| Dec. 30, 2013 | CEO | 18,147 | $111.60 | Sell | $2,025,205.20 | |
| Dec. 27, 2013 | CEO | 18,147 | $113.15 | Sell | $2,053,333.05 | |
| Dec. 26, 2013 | CEO | 21,981 | $111.95 | Sell | $2,460,772.95 | |
| Dec. 24, 2013 | CEO | 18,149 | $114.05 | Sell | $2,069,893.45 | |
| Dec. 23, 2013 | CEO | 5,743 | $109.71 | Sell | $630,064.53 | |
| Dec. 20, 2013 | CEO | 18,149 | $86.72 | Sell | $1,573,881.28 | |
| Dec. 20, 2013 | COO | 8,250 | $87.84 | Sell | $724,680.00 | |
| Dec. 19, 2013 | EVP | 6,000 | $86.45 | Sell | $518,700.00 |
Insiders are both buying and selling United Therapeutics Corporation stock.
The insider traders at United Therapeutics Corporation are: Martine A Rothblatt, Paul A Mahon, Roger Jeffs, Martine A. Rothblatt, Martine Rothblatt, Christopher Causey, Raymond Dwek, John Maxim Ferrari, Michael Benkowitz, Christopher Patusky, Paul Mahon, David Zaccardelli, Richard Giltner, Nilda Mesa, James Edgemond, Tommy G Thompson, Louis W Sullivan, Judy D Olian, Paul A. Mahon, Jan Malcolm, Ray Kurzweil, Tommy G. Thompson, MAHON PAUL A, Louis Sullivan, Judy D. Olian, R Paul Gray, and DWEK RAYMOND
The most active insider trader at United Therapeutics Corporation is Martine A Rothblatt with 393 trades.
Martine A Rothblatt has sold the most United Therapeutics Corporation stock with a total value of $386,981,200.91.
Martine A Rothblatt has bought the most United Therapeutics Corporation stock with a total value of $1,217,751.60.
The most recent insider trade for United Therapeutics Corporation was on Feb. 25, 2026.
The single biggest insider buy for United Therapeutics Corporation was from Martine A Rothblatt with a total value of $466,650.00 on Dec. 21, 2012.
The single biggest insider sell for United Therapeutics Corporation was from Michael Benkowitz with a total value of $10,679,625.00 on Feb. 9, 2026.
